Clinical Trials on Pre-cancerous Lymphoproliferative Disorders in Australia

Total 821 results

Charite University, Berlin, Germany

Terminated

Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

Post-transplantation Lymphoproliferative Disorder

Australia, France, Germany, Sweden
Garvan Institute of Medical Research
Weizmann Institute of Science

Active, not recruiting

Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes (PREDICT)

Type 2 Diabetes Mellitus | Pre Diabetes

Australia
Clinuvel Pharmaceuticals Limited

Completed

Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

Polymorphic Light Eruption (PLE)

Austria, Australia, United Kingdom
Resverlogix Corp
Nucleus Network Ltd; Baker Heart and Diabetes Institute

Completed

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

Diabetes

Australia
Bayside Health

Completed

Efficacy Study of Outpatient Therapy for Lymphoma

Non-Hodgkin's Lymphoma | Hodgkin's Disease

Australia
Charite University, Berlin, Germany

Completed

Risk Stratified Sequential Treatment for CD20-positive PTLD (PTLD-1/3)

Posttransplant Lymphoproliferative Disorder | PTLD

Australia, France, Germany, Sweden, Belgium, Italy, Poland
Trans Tasman Radiation Oncology Group
Australasian Leukaemia and Lymphoma Group

Completed

Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

Primary Central Nervous System Lymphoma

Australia, New Zealand
Celgene Corporation

Completed

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Ireland, Spain, Australia, Austria, United Kingdom
Dizal Pharmaceuticals

Not yet recruiting

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

Australia
Universitaet Innsbruck
Medical University Innsbruck

Completed

Altitude, Exercise and Glucose Metabolism in Pre-diabetic Men

Diabetes

Austria
Trans Tasman Radiation Oncology Group
Australasian Leukaemia and Lymphoma Group

Completed

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Follicular Lymphoma

Australia, New Zealand, Canada
University of Sydney

Active, not recruiting

Sub-Study of the PREVIEW Study Australia

Obesity | Pre-diabetes

Australia
Australasian Leukaemia and Lymphoma Group

Recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX)

Mantle Cell Lymphoma | Mantle Cell Lymphoma Refractory

Australia
Bayside Health

Completed

Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Non-Hodgkin's Lymphoma (CD20+)

Australia
TG Therapeutics, Inc.

Completed

Study of TG-1801 in Subjects With B-Cell Lymphoma

B-Cell Lymphoma

Australia
Monash University

Recruiting

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (RATIONALISE)

Hypogammaglobulinemia | Haematological Malignancy

Australia
Marcus Saemann

Completed

Glucose Control in Pre-Diabetic Renal Transplant Patients (GCPD)

Kidney Transplantation | Impaired Glucose Tolerance

Austria
Peter MacCallum Cancer Centre, Australia

Recruiting

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (LEVERAGE)

Follicular Lymphoma

United States, Australia
Bayside Health

Terminated

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Woolcock Institute of Medical Research

Not yet recruiting

CPAP and Glucose Metabolism in Non-Diabetic OSA Subjects

Obstructive Sleep Apnea | Pre-diabetes

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
Peter MacCallum Cancer Centre, Australia
Melbourne Health

Completed

NMP in Relapsed / Refractory Myeloma

Multiple Myeloma

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Multiple Myeloma

Australia
GlaxoSmithKline

Withdrawn

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Cancer

Australia
Peter MacCallum Cancer Centre, Australia
Celgene Corporation; Janssen-Cilag Ltd.

Unknown

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Multiple Myeloma

Australia
Bayside Health

Unknown

Atorvastatin in Myeloma

Myeloma

Australia
Murdoch Childrens Research Institute

Not yet recruiting

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. (PEGASUS)

Hodgkin Lymphoma | Non Hodgkin Lymphoma

Australia
PharmaEngine

Recruiting

A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

Acute Myeloid Leukemia | Lymphoma, Mantle-Cell

Australia
Ichnos Sciences SA

Not yet recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
The Leukemia and Lymphoma Society

Completed

A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone

Lymphoma | Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia
AbbVie

Withdrawn

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Multiple Myeloma

Australia
Cancer Trials Australia
Human Genome Sciences Inc.

Unknown

A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Symptomatic Waldenstroms Macroglobulinaemia

Australia
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Australia
IGM Biosciences, Inc.

No longer available

Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

Relapsed/Refractory Non-Hodgkin Lymphomas

Australia, Korea, Republic of, Spain
Anne Birgitte Raben
University of Nottingham; University of Helsinki; Wageningen University; University... and other collaborators

Completed

Effect of Diet and Physical Activity on Incidence of Type 2 Diabetes (PREVIEW)

Obesity | Pre-diabetes

Spain, Denmark, Australia, Bulgaria, Finland, Netherlands, New Zealand, United Kingdom
Peter MacCallum Cancer Centre, Australia
Janssen-Cilag Ltd.

Completed

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Novartis

Active, not recruiting

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Mantle Cell Lymphoma Recurrent

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (EpiBrentlen)

Hodgkin Lymphoma | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

Australia
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

Mantle Cell Lymphoma

Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Lymphoproliferative Disorder

Canada, United States, Australia, New Zealand
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaborators

Recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab. (TOP-FLOR)

Follicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IV

Australia
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Spain, Australia, Denmark, Norway
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
Queensland Institute of Medical Research
National Health and Medical Research Council, Australia; Australian Department... and other collaborators

Completed

Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas (EPL)

Lymphoma

Australia
Bayside Health

Completed

Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma

Non-Hodgkin's Lymphoma | Hodgkin's Disease

Australia
Arbeitsgemeinschaft medikamentoese Tumortherapie

Recruiting

AGMT Austrian Lymphoma Registry

Lymphoma

Austria
Children's Cancer and Leukaemia Group

Completed

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Leukemia

United Kingdom, Australia

Clinical Trials on Pre-cancerous Lymphoproliferative Disorders in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations